Creative Biolabs has unveiled a suite of advanced neuroscience platforms designed to accelerate brain research amid rising global rates of neurodegenerative diseases. The World Health Organization reports more than 55 million people currently live with dementia worldwide, with Alzheimer's disease accounting for up to 70% of dementia cases, creating urgent demand for improved research tools.
The company's new Schwann Cell Assay platform addresses peripheral nervous system research needs by enabling isolation of Schwann cells from human, mouse, and rat species. This platform supports co-culture systems with neurons, allowing scientists to assess critical functional measures including neurotrophic factor secretion and myelination potential, both essential for regenerative medicine applications.
For central nervous system research, Creative Biolabs launched its microglia phagocytosis assay service, which utilizes live-cell imaging and fluorescently labeled bioparticles. This technology enables researchers to visualize microglial phagocytic function in real time, providing valuable insights into neuroinflammation responses and pathological protein aggregate clearance mechanisms.
The company has also developed comprehensive preclinical assessment services for Alzheimer's disease models, featuring both 2D and 3D platforms that replicate key disease aspects including amyloid deposition, tauopathy, and neuroinflammation. These models can represent both familial and sporadic Alzheimer's disease forms, originating from patient-derived induced pluripotent stem cells, offering more rigorous contexts for drug screening and mechanistic studies.
A company spokesperson stated their straightforward aim is to provide researchers with the right resources to advance neuroscience. More information about their neuroscience solutions is available at https://neuros.creative-biolabs.com/.
